Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: A meta-analysis

16Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Ovarian cancer is a prominent public health problem which affects people all around the world. Platinum-based chemotherapy is a common treatment for ovarian cancer, however, the effectiveness of chemotherapy varies from patient to patient. The excision repair cross complementation group 1 (ERCC1) protein may mediate chemotherapy resistance. A meta-analysis was conducted to explore whether platinum-based chemotherapy effectiveness could be attributed to the ERCC1 C19007T polymorphisms. Methods: Seven major databases (EMBASE, Web of Science, Pubmed, Springer Link, Chinese National Knowledge Infrastructure (CNKI), EBSCO and Science Direct databases) were searched for eligible studies. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the results. Results: In this meta-analysis, 1169 subjects (425 non-responders and 744 responders) from 8 studies were included. The overall OR (C vs. T alleles) using random model was 1.07 (95% CI 0.75-1.52, P = 0.7), which was not statistically significant. Moreover, there was no significant difference in the analysis by race. Conclusion: There is no association between the ERCC1 C19007T polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer. The polymorphism did not have a significant impact on platinum-based chemotherapy in non-responders and responders.

References Powered by Scopus

Bias in meta-analysis detected by a simple, graphical test

42603Citations
N/AReaders
Get full text

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

1595Citations
N/AReaders
Get full text

Publication bias and dissemination of clinical research

375Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The association of polymorphisms in nucleotide excision repair genes with ovarian cancer susceptibility

27Citations
N/AReaders
Get full text

Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin

15Citations
N/AReaders
Get full text

Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort

12Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Tang, N., Lyu, D., Zhang, Y., & Liu, H. (2017). Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: A meta-analysis. BMC Women’s Health, 17(1). https://doi.org/10.1186/s12905-017-0393-z

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

56%

Researcher 5

31%

Lecturer / Post doc 2

13%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 5

31%

Biochemistry, Genetics and Molecular Bi... 5

31%

Medicine and Dentistry 4

25%

Nursing and Health Professions 2

13%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free